Drug intelligence / Profile preview

KN203

Development stage: Discontinued
Lead developer: KeyNeurotek Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

KN203 is a small molecule µ-opioid receptor (MOR) agonist that was developed by KeyNeurotek Pharma GmbH for the treatment of overactive bladder (OAB) and urgency-frequency syndrome. It was the first compound in its class to be specifically investigated for OAB, operating through the activation of µ-opioid receptors to modulate bladder muscle contraction. The drug reached Phase 2 clinical development, where it was evaluated in a double-blind, randomized, placebo-controlled proof-of-concept trial involving German women with OAB. However, development ceased following the dissolution of KeyNeurotek Pharma.

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on KN203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KN203.

Explore the full profile